Drug Profile
Abrocitinib - Pfizer
Alternative Names: CIBINQO; Cibinqo; JAK 1 inhibitor - Pfizer; PF 04965842; PF-4965842Latest Information Update: 05 Feb 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Developer National Institute of Diabetes and Digestive and Kidney Diseases; Pfizer
- Class Amines; Anti-inflammatories; Antihyperglycaemics; Antipsoriatics; Cyclobutanes; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules; Sulfonamides
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Atopic dermatitis
- Phase II Prurigo nodularis; Pruritus; Sarcoidosis; Type 1 diabetes mellitus
- Discontinued Lupus vulgaris; Plaque psoriasis
Most Recent Events
- 31 Jan 2024 Glenmark Pharmaceuticals and Pfizer agree to co-promote and market Abrocitinib in India for Atopic dermatitis
- 31 Jan 2024 Launched for Atopic dermatitis (In adolescents, In the elderly, Treatment-experienced, In adults) in USA, Iceland, Norway, Liechtenstein, European Union, Japan, Japan, Japan, China (PO)
- 31 Jan 2024 Registered for Atopic dermatitis (In adolescents, In the elderly, Treatment-experienced, In adults) in India (PO)